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Background: Preliminary evidence suggests cancer- and chemotherapy-related autonomic nervous system (ANS)
dysfunction may contribute to the increased cardiovascular (CV) morbidity- and mortality-risks in cancer survivors.
However, the reliability of these findings may have been jeopardized by inconsistent participant screening and
assessment methods. Therefore, good laboratory practices must be established before the presence and nature of
cancer-related autonomic dysfunction can be characterized. The purpose of this study was to assess the feasibility
of conducting concurrent ANS and cardiovascular evaluations in young adult cancer patients, according to the
following criteria: i) identifying methodological pitfalls and proposing good laboratory practice criteria for ANS
testing in cancer, and ii) providing initial physiologic evidence of autonomic perturbations in cancer patients
using the composite autonomic scoring scale (CASS).
Methods: Thirteen patients (mixed diagnoses) were assessed immediately before and after 4 cycles of chemotherapy.
Their results were compared to 12 sex- and age-matched controls. ANS function was assessed using standardized tests
of resting CV (tilt-table, respiratory sinus arrhythmia and Valsalva maneuver) and sudomotor (quantitative sudomotor
axon reflex test) reactivity. Cardiovascular reactivity during exercise was assessed using a modified Astrand-Ryhming
cycle ergometer protocol. Our feasibility criteria addressed: i) recruitment potential, ii) retention rates, iii)
pre-chemotherapy assessment potential, iv) test performance/tolerability, and v) identification and minimizing
the influence of potentially confounding medication. T-tests and repeated measures ANOVAs were used to assess
between- and within-group differences at baseline and follow-up.
Results: The overall success rate in achieving our feasibility criteria was 98.4 %. According to the CASS, there was
evidence of ANS impairment at baseline in 30.8 % of patients, which persisted in 18.2 % of patients at follow-up,
compared to 0 % of controls at baseline or follow-up.
Conclusions: Results from our feasibility assessment suggest that the investigation of ANS function in young adult
cancer patients undergoing chemotherapy is possible. To the best of our knowledge, this is the first study to report
CASS-based evidence of ANS impairment and sudomotor dysfunction in any cancer population. Moreover, we provide
evidence of cancer- and chemotherapy-related parasympathetic dysfunction – as a possible contributor to the
pathogenesis of CV disease in cancer survivors.
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Despite therapeutic advances, cancer survivors remain at
higher risk of disease- and treatment-related CV mor-
bidity and mortality [1, 2]. Autonomic impairment, or
neuropathy, is a nervous system disorder affecting the
control of involuntary functions, including, digestion,
heart rate, blood pressure, and perspiration. Preliminary
associations between autonomic impairment-related CV
dysfunction and increased risk/severity of CV disease
and all-cause mortality have been proposed by a number
of reviews of epidemiological- and clinical trial-based re-
search [3–5]. Various anti-cancer chemotherapies may
further affect the function of the autonomic and CV sys-
tems. Using both short duration and 24 h recordings, di-
minished heart rate (HR) variability has been reported in
patients treated with vincristine [6], doxorubicin [7],
various combination therapies [8, 9], and in some [10],
but not all [11], patients treated with paclitaxel. Aber-
rant blood pressure variability and maladaptive ortho-
static responses have been observed in patients treated
with paclitaxel, taxanes, vinca alkaloids and cisplatin
[12–15] – although the mechanisms were not always
clear. However, these studies lacked consistency in their
selection/execution of autonomic challenges, application
of their eligibility and testing criteria. More specifically,
several of these trials included participants with ad-
vanced age and pre-cancer comorbidities (i.e., diabetes
and heart disease), both of which are known perturb
ANS reflex responses. Furthermore, many failed to in-
clude key methodological details required to compare
between trials. As such, they provide very little clinical
relevance, and there remains insufficient evidence to
make any conclusions regarding the presence or nature
of cancer-related autonomic dysfunction.
Interestingly, regular aerobic exercise training has been
shown to improve indices of CV health (i.e., HR variabil-
ity) in various CV disease (CVD) populations [16–20].
As such, aerobic exercise may be effective in improving
similar CV outcomes in cancer patients. Although a uni-
fying mechanism of cancer-related CVD development
has yet to be elucidated, a potential contributing factor
may be the effects of cancer and anticancer therapies on
ANS function. This relationship is often suggested in the
literature but has yet to be clearly defined [3]. This line
of investigation may be most important/relevant within
the young adult cancer population for two reasons. First,
ANS function is known to decline with age and is influ-
enced by existing comorbidities [21]. By virtue of their
age, young adult cancer patients are the most likely to
have normal ANS reflexes. Second, given their average
5 years survival rates and greater number of years of life
ahead of them [22, 23], the premature development of
CVD in young adult cancer survivors is likely to account
for many more years of life affected per individual.The purpose of this study was to assess the feasibility
of conducting concurrent ANS and CV evaluations in
young adult cancer patients undergoing treatment for
various cancers. However, we were concerned that, given
the heterogeneity of the population (i.e., diagnoses and
treatments) and the complexity of the reflex responses,
ANS testing during cancer treatment may not provide
reliable evidence of ANS dysfunction. Beyond this, our
additional feasibility concerns included: i) recruitment
potential (given that young adults account for only 10 %
of cancer diagnoses, and we recruited at time of diagno-
sis), ii) retention rates (anticipated difficulty with compli-
ance and follow-up), iii) capacity to establish a baseline
assessment (variable time between initial diagnosis and
commencement of systemic therapy), iv) performance
and tolerability of the ANS and CV test battery compo-
nents. Furthermore, we also sought to document and re-
port the prevalence of confounding medication use, as
they may perturb ANS and CV reflex responses in re-
lated lines of research. Our primary objectives were to
identify the methodological pitfalls and propose good la-
boratory practice criteria for future autonomic testing in
cancer. Our secondary – hypothesis generating – object-
ive was to use modern clinical assessment techniques to
provide evidence of autonomic perturbations in young
adult cancer patients as a potential precursor to the de-
velopment of CVD. According to pilot study guidelines
[24], our research questions and methods were designed
to reflect those to be used in a subsequent, larger inves-
tigation of the subject. Our primary research question
was developed to determine if cancer or chemotherapy
have a significant impact on ANS and CV function in
young adult cancer patients. We hypothesized that young
adults with cancer would demonstrate an increased inci-
dence and severity of cancer- and chemotherapy-related
ANS and CV dysfunction (vs. controls); and, that the ANS
dysfunction would significantly impair the exercise re-
sponse of young adult cancer patients to, and in recovery
from, a brief submaximal exercise challenge.
Methods
Recruitment took place from March 2010 to July 2011.
Eligible patients with all stages of disease, aged 18–45
with an Eastern Cooperative Oncology Group perform-
ance status (ECOG) ≤ 2, were recruited from the McGill
Adolescent and Young Adult Oncology Program and the
Segal Cancer Centre of the Jewish General Hospital,
Montreal Quebec. Healthy control subjects (age- and
gender-matched hospital staff and university students)
were recruited by word of mouth, on a case-by-case
basis. Exclusion criteria: i) use of any medications, at T1,
that interfered with autonomic or CV function, ii) intrin-
sic cardiac disease or ANS-perturbing comorbidity (e.g.,
arrhythmia, intraventricular conduction defects, evidence
Fig. 1 Sequence of tests
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betes, hypertension, neuropathy, seizure disorder) and iii)
an inability to perform any of the baseline (T1) ANS or
CV challenges due to tumor location. In accordance with
our feasibility objectives, detailed records of recruitment,
retention, testing and confounding medication use were
kept. Jewish General Hospital and Concordia University
institutional review boards both approved this study
(protocol # 04–032).
Oncologist clearance and verbal patient consent were
obtained prior to explaining the study. Patients reviewed
the informed consent and were able to ask questions.
Those agreeing were given detailed pre-test instructions
according to best practices of ANS and CV testing [21,
25]. T1 was booked within 24 h of recruitment. Informed
consent was signed at T1. All patients underwent ANS
and CV evaluations at T1 (post-diagnosis and pre-
chemotherapy) and follow-up (T2; after their 4th, and one
week prior to their 5th chemotherapy treatment – hypothe-
sized to be the intra-treatment period least susceptible to
the influence of confounding medication use).
All procedures were conducted within the hospital’s
Autonomic Reflex Laboratory. Self-reported fatigue was
measured using the Brief Fatigue Inventory [26] – com-
prised of 10 questions, scored from 0–10, with a total
possible score of 100 arbitrary units (a.u.). Self-reported
physical activity levels were reported and expressed as
MET∙hrs∙week−1. Following standard protocols [21], theTable 1 Feasibility results
Feasibility Criteria Target
I. Patient recruitment & access
I.i Comorbidity & medication free < 5 %
I.ii Patient identification rate >40 patient/year
II. Subject retention >95 %
III. Baseline establishment
III.i Days between diagnosis & T1 ≤9 days
III.ii Time-related testing constraints <20 % missed
IV. Test performance & tolerability
IV.i Test performance >95 % test compl
IV.ii Testing tolerance <1 % AEs/< 10 %
V. Potentially confounding medication use N/A
OEP otherwise eligible participants, AE adverse events, AC active complaintsnon-invasive battery of tests used at rest (respiratory
sinus arrhythmia (RSA), Valsalva maneuver (VM), tilt-
table and quantitative sudomotor axon reflex test
(QSART)) provided information concerning cardiovagal,
sympathetic adrenergic vasomotor and cardiomotor, as
well as postganglionic sympathetic cholinergic sudomo-
tor function [27, 28]. The severity and localization of the
type and sites of autonomic dysfunction were graded
and compared using a validated composite autonomic
scoring scale (CASS) [27, 28]. Immediately following the
resting ANS protocol, the subjects were transferred to
an adjacent evaluation room to perform a brief, 6-min,
submaximal exercise challenge on a cycle ergometer [29]
(Fig. 1). The exercise test was proposed to obtain a func-
tional assessment of the indices of CV function (e.g.,
central (e.g., HR variability, HR, stroke volume and car-
diac output) and peripheral (blood pressure and systemic
vascular resistance)) that correlate with the ANS testing.
In establishing our feasibility criteria (FC), several im-
portant factors were weighed. First, previous investiga-
tions of ANS function in cancer [6, 8–10, 12, 13, 30–33]
often had small sample sizes, did not establish pre-
treatment baselines, included a wide age-range of partici-
pants and lacked sufficient and consistent methodological
and results reporting. Second, in accordance with pilot
study guidelines [24], and given that our trial did not in-
clude an intervention, we established more stringent FC
to reflect the factors that could hinder a larger, moreActual % Attained
3.6 % (1/28 OEP) 100 %
>46 patients/year 100 %
92.3 % 97.2 %
9.1 days 99.9 %
27 % missed 91 %
etion 94.3 test completion 99.3 %
ACs 0.83 % AE / 5.1 % AC 100 % / 100 %
T1: 15.4 % T2: 83.3 %
Fig. 2 Subject recruitment and testing
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tory practices for ANS testing in cancer, we based most
decisions for our FC on the combined results of recent,
in-treatment, randomized controlled cancer-exercise trials
[34–37] and McGill Adolescent and Young Adult Oncol-
ogy Program clinic data [Palumbo M, Kavan P: Adolescent
and Young Adult Oncology: The Challenge in Serving a
Unique, Underserved Population - Five Year Experience
of The McGill University Adolescent and Young Adult
Oncology Program, Unpublished 2008 – 2013] which in-
cluded comprehensive reports of key methods, recruit-
ment strategies, trial design and participant flow. In the
end, our feasibility criteria addressed i) patient recruitment
and access (i.e., (a) prevalence of baseline comorbiditiesTable 2 Baseline subject characteristics
Control mean ± SD Patient mean ± SD
n 11 12
Sex (women) 55 % (n = 6) 67 % (n = 8)
Age (years) 33.8 ± 8.1 35.0 ± 8.9
Weight (kg) 66.3 ± 12.5 66.5 ± 11.5
BMI (kg/m−2) 23.0 ± 2.1 23.0 ± 3.5
BFI 15.5 ± 13.2 27.3 ± 14.2b
PA level (MET · hrs∙week−1) 26.3 ± 22.9 7.5 ± 7.6a
SDstandard deviation, BMI body mass index, BFI brief fatigue inventory,
PAphysical activity, MET metabolic equivalent of task
ap ≤ 0.05; bp = 0.051and confounding medication use, and (b) identification of
eligible patients), ii) subject retention rates, iii) capacity to
establish a post-diagnosis/pre-chemotherapy baseline (i.e.,
(a) number of days between diagnosis and initiation of
treatment, and (b) any time-related testing constraints (e.g.,
scheduling conflicts, physician availability)), iv) test per-
formance, v) test tolerability, and vi) prevalence of poten-
tially confounding medication use.
Severity of autonomic dysfunction was assessed using
the CASS [27]. Spectral analysis of HR and baroreflex
function assessed at rest and during head-up tilt, using
established methods and procedures [38–40], provided
additional indices of the integrity of cardiac autonomic
and sympathetic vasomotor innervation [40, 41]. To
evaluate the influence of disease proliferation on our
endpoints, baseline comparisons were made using
standard t-tests. To assess the impact of exposure to
chemotherapy on our endpoints, group-by-time inter-
actions were evaluated using 2x2 repeated measures
ANOVAs. Based on recent pilot study methodological
recommendations, the feasibility-nature of the investi-
gation, and the anticipated small size and heteroge-
neous nature of our sample, a power analysis, subgroup
analyses or adjustments for relevant covariates and po-
tential effect modifiers were not performed [24]. Fur-
thermore, given the feasibility-nature of the study,
significance was set at α = 0.05 and not adjusted for mul-
tiple comparisons.
Table 3 Patient diagnosis and treatment characteristics
Cancer types Treatment protocol (# of patients)
Breast 4 cycles FEC + Paclitaxel (n = 1)
4 cycles AC (n = 4)
Gastrointestinal
Pancreatic FOLFIRINOX x 3 + Gemcitabine x 1
(n = 1)
Colon Xelox x 4 (n = 1)
Anal Mitomycin C + 5 FU x 4 (n = 1)
Hematological
Hodgkin’s Lymphoma ABVD (n = 2)
Non-Hodgkin’s Lymphoma R-CHOP (n = 1)
Other
Adenocarcinoma (unknown origin) C-Pacli (n = 1)
Parotid (acinic cell carcinoma) C-Pacli (n = 1)
FEC fluorouracil epirubicin cyclophosphamide, AC adriamycin
cyclophosphamide, FOLFIRINOX, folinic acid fluorouracil irinotecan oxaliplatin, 5
FU fluorouracil, ABVD adriamycin bleomycin vinblastine dacarbazine, R-CHOP
rituximab + cyclophosphamide hydroxyldaunoreubicin oncovin (vincristine)
prednisone, C-Pacli carboplatin + paclitaxel
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Primary results: feasibility outcomes
We were 98.4 % successful in achieving our target FC
(Table 1).
Secondary results: exploratory self-report and physiology
outcomes
Baseline demographic and self-report results
Thirteen cancer patients and 12 sex-and age-matched con-
trols were tested at T1 (Fig. 2). Subject demographic and
medical information is presented in Tables 2, 3 and 4. Study
groups were closely matched in gender, age and body mass
index. There was a significant difference at T1, t(21) = 2.594,
p = 0.017, in weekly physical activity levels (mean ± SD)Table 4 Patient disease staging and functional status
# of Patients (%)
Staging at diagnosis Stage I 1 (8)
Stage II 6 (46)
Stage III 3 (23)
Stage IV 3 (23)
Performance status (0–4) Baseline
ECOG 0 3 (23)
ECOG 1 8 (62)
ECOG 2 2 (15)
Follow-up
ECOG 0 4 (33)
ECOG 1 7 (58)
ECOG 2 1 (8)between the patient (7.5 ± 7.6 MET∙hrs∙week−1) and control
groups (26.3 ± 22.9 MET∙hrs∙week−1), respectively. There
was also a trend towards significance in T1, t(21) = 2.066,
p = 0.051, in Brief Fatigue Inventory scores (mean ± SD;
out of a possible 100 a.u.) between the patient (27.3 ±
14.2 a.u.) and control groups (15.5 ± 13.2 a.u.),
respectively.CASS results
T2 measurements were collected a mean of 14.3 weeks
and 19.0 weeks after T1 for patients and controls, re-
spectively. 2x2 repeated measures ANOVAs revealed sig-
nificant, or near significant, between-group differences
for all dependent variables found in Table 5. Autonomic
dysfunction is defined as a minimum score of two in any
of the three CASS domains (i.e., cardiovagal, adrenergic
and sudomotor), or a minimum score of one in at least
two domains – out of a total possible score of 10 [42].
After applying the CASS criteria, the individual (Figs. 3
and 4) and group results (Tables 6 and 7) demonstrate
mild to moderate ANS dysfunction at T1 (1.23 ± 1.59;
mean ± SD), with slight improvement in ANS function at
T2 (0.67 ± 0.99). The observed group main effects were
the patients’ cardiovagal [F(1,21) = 4.575, p = 0.044] and
total [F(1,21) = 5.975, p = 0.023] CASS scores were signifi-
cantly higher than controls. Although the difference be-
tween patients’ and controls’ sudomotor CASS scores did
not reach significance [F(1,21) = 3.702, p = 0.068], the
number of patients who had abnormal or borderline ab-
normal QSART scores was significantly higher than con-
trols [F(1,21) = 4.830, p = 0.039]. Neither group displayed
evidence of severe ANS or CV dysfunction at either test-
ing time point. Unmanaged, disease- and treatment-
related complications prevented one patient from
attempting the VM at T1, and a different patient from
attempting the VM and tilt-table test at T2. Two patients
and two controls demonstrated orthostatic intolerance
during the tilt-table test at T1 and T2 (one subject from
each group at each time point).Exercise testing results
At T1, predicted maximal oxygen uptake (VO2max) was
significantly lower in the patient group (2.54 ± 0.70 ml
O2∙min
−1; mean ± SD) than in controls (3.37 ± 0.99 ml
O2∙min
−1, t(19) = 2.172, p = 0.043). The observed group
main effects was the patients’ predicted VO2max (2.52 ±
0.36 ml O2∙min
−1; mean ± SE) was significantly lower
than controls (3.36 ± 0.36 ml O2∙min
−1; F(1,18) = 5.493,
p = 0.031). In addition, compared to controls, patients’
HR recovery improved significantly following treatment
[F(1,15) = 4.938, p = 0.042], which mirrored the direction
of change in the CASS score. Again, disease- and
treatment-related complications prevented one patient
Table 5 Main group effects
Test component Control mean ± SE Patient mean ± SE Mean difference (95 % CI) p Partial eta2
Tilt-Table HR Differences
Baseline 56.39 ± 3.02 73.07 ± 2.88 16.7 (8.0 to 25.4) 0.001 0.46
Tilt 1 75.9 ± 4.09 93.48 ± 3.90 17.6 (5.8 to 29.4) 0.006 0.34
Tilt 2 78.6 ± 4.09 95.2 ± 3.90 16.6 (4.8 to 28.4) 0.008 0.31
Tilt Total 77.26 ± 4.05 94.34 ± 3.87 17.1 (5.4 to 28.8) 0.007 0.33
Bike HR Differences
Baseline 69.85 ± 3.92 81.27 ± 3.92 11.4 (−0.2 to 23.1) 0.054 0.19
Warm-up 73.36 ± 4.42 84.53 ± 4.42 11.2 (−1.9 to 24.3) 0.09 0.15
Loading 78.99 ± 4.27 88.59 ± 4.27 9.6 (−3.1 to 22.3) 0.13 0.12
2nd minute 121.5 ± 5.75 128.53 ± 5.75 7.0 (−10.1 to 24.1) 0.399 0.04
6th minute 137.1 ± 4.83 144.8 ± 4.83 7.7 (−6.6 to 22.1) 0.274 0.07
Stop 109.36 ± 4.79 124.71 ± 4.79 15.3 (1.1 to 29.6) 0.036 0.22
Cool down 91.9 ± 4.83 106.1 ± 4.83 14.2 (−0.2 to 28.5) 0.052 0.19
QSART
Baseline Sweat Rates
Forearm 70.96 ± 5.03 62.13 ± 4.82 −8.8 (−23.3 to 5.7) 0.219 0.07
Proximal Leg 66.68 ± 4.86 57.75 ± 4.65 −8.9 (−22.9 to 5.1) 0.198 0.08
Distal Leg 68.23 ± 4.97 59.42 ± 4.76 −8.8 (−23.1 to 5.5) 0.214 0.07
Foot 83.68 ± 4.86 68.17 ± 4.65 −15.5 (−29.5 to −1.5) 0.031 0.20
# Sites <10 % of normal 0.18 ± 0.31 1.13 ± 0.30 0.95 (0.05 to 1.8) 0.039 0.19
SE,standard error; CI, confidence interval
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patient from attempting the exercise test at T2.
Discussion
In the present study, we aimed to establish recommen-
dations and guidelines upon which future investigations
of ANS function in cancer could be planned and imple-
mented. The principle finding of a combined 98.4 % suc-
cess in achieving our FC suggests that a larger scale
investigation of cancer-related autonomic dysfunction in
young adults is possible.
Acute and chronic autonomic impairments have dele-
terious effects on quality of life and survival in health
and a variety of disease states [3]. Initial evidence of
cancer- and chemotherapy-related ANS dysfunction
have been shown here and in the literature (both during
and post-treatment) [6–10, 12, 30, 32, 33, 43–48]. How-
ever, the methodology in previous ANS-cancer research
has been inconsistent. Therefore, we based our feasibility
assessment upon methodologically robust exercise on-
cology trials. This basis may be particularly relevant
given the potential for using exercise as a modality to
preserve and restore ANS and CV function in cancer, as
has been described in other populations [49]. In an at-
tempt to inform good laboratory practice, and drawing
from our collective experience, we propose the followingmethodological considerations to facilitate future studies
of autonomic function in cancer (Table 8).
In keeping with our stated objective to facilitate hypoth-
esis generation for future research, the findings of this ex-
ploratory investigation include significant between-group
differences in cardiovagal and total CASS scores and a
significantly increased prevalence of sudomotor dys-
function – potentially suggestive of mild to moderate,
cholinergic-mediated, impairment of ANS function in
our patient group versus controls. We also report, com-
pared to controls, significantly greater HRs during the
tilt table (T1-T2) and Astrand-Ryhming (baseline and re-
covery periods) challenges (T1-T2), and lower predicted
VO2max (T2 only). We observed a slight improvement in
ANS and CV function at T2 (CASS and post exercise HR
recovery). However, given the cumulative nature of chemo-
toxicity, it is possible that greater treatment effects would
have been observed if T2 measures were collected follow-
ing treatment vs. just four cycles.
The cardiovagal, adrenergic, and sudomotor CASS
components reflect the integrity of parasympathetic,
sympathetic, and sudomotor sympathetic branches of
the ANS, respectively [27]. Supporting the evidence for
paraneoplastic-related CV and autonomic dysfunction in
cancer [9, 30, 33, 47, 50, 51], our baseline assessment re-
vealed evidence of CV and ANS differences between
Fig. 3 Individual RSA (top) and Valsalva Ratio (bottom) scores for patients and controls at baseline and follow-up. Note Data points have been
color-coded within each group and according to subject. Circular data points reflect scores or measurements falling within normal age- and
gender-related ranges. Whereas triangular and square data points reflect scores or measurements > 50 % and < 50 %, respectively, of the lower
normal age- and gender-related limits. Black vertical bars and corresponding values represent group means for each time point
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table test, as well as at baseline and in recovery from the
bike test, may reflect inadequate parasympathetic (or
acetylcholine-mediated) restraint of HR. Alternatively,
the observed HRs differences may be an artifact of the
poorer aerobic fitness levels of our patient group and
not be autonomically-mediated. In addition, there was asignificant between-group difference in the number of
abnormal QSART sites in our patient group (vs con-
trols). This too may reflect an acetylcholine-mediated
mechanism of ANS dysfunction. Contrary to reports of
increased ANS impairment during or following treat-
ment [30, 33], and similar to the findings of Turner
et al. [9], our results demonstrated persistent, yet slightly
Fig. 4 Individual QSART scores at the forearm (top left), proximal leg (top right), distal leg (bottom left) and foot (bottom right) for patients and controls at baseline and follow-up. Note Data points
have been color-coded within each group and according to subject. Circular data points reflect scores or measurements falling within normal age- and gender-related ranges. Whereas triangular
and square data points reflect scores or measurements > 50 % and < 50 %, respectively, of the lower normal age- and gender-related limits. Black vertical bars and corresponding values represent

































Patients 13 2 (15.4) 0 (0.0) 2 (15.4) 30.8 12 4 (33.3) 0 (0.0) 0 (0.0) 33.3
Controls 12 0 (0.0) 0 (0.0) 0 (0.0) 0 11 1 (9.1) 0 (0.0) 0 (0.0) 9.1
Cardiovagal function
Patients 12 0 (0.0) 2 (16.7) 3 (25.0) 41.7 11 2 (18.2) 1 (9.1) 0 (0.0) 27.3
Controls 12 1 (8.3) 0 (0.0) 0 (0.0) 8.3 11 1 (9.1) 1 (9.1) 0 (0.0) 18.2
Adrenergic function
Patients 11 0 (0.0) 0 (0.0) 0 (0.0) 0.0 12 0 (0.0) 0 (0.0) 0 (0.0) 0.0
Controls 12 0 (0.0) 0 (0.0) 0 (0.0) 0.0 11 0 (0.0) 0 (0.0) 0 (0.0) 0.0
Normative values taken from [66, 67]
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Given the evidence supporting the correlation between
higher resting parasympathetic tone and higher aerobic
fitness levels [51–58], the potentially confounding influ-
ence of aerobic fitness levels between groups must be
considered when interpreting our cardiovagal results.
Contrary to reports of chemotherapy-induced attenuation
of HR variability [6, 32, 43], spectral analysis of short-term
HR variability recordings in our study (obtained during
pre-tilt rest) did not reveal any observable fluctuation in
parasympathetic activity (as indicated by the high-
frequency domain). This is consistent with the findings
of Ekholm et al. [10], who suggested that the acute
chemotherapy-induced changes may be more subtle
and therefore not as easily detected using short-term
(vs. 24 h) recordings. Finally, to the best of our know-
ledge, we are the first to report QSART evidence of
sudomotor impairment in cancer. Although there was a
slight improvement in sudomotor function at T2 (shift
in CASS scores toward more mild impairments), our
assessment revealed a slight shift in which five out of
the eleven patients were affected.
The effect of ANS impairments on survivorship and
long-term quality of life remain unclear. Related research
has demonstrated persistent ANS impairment in cancer
survivors, with and without advanced disease [8, 32, 43, 46,
47]. However, the reported methods varied in their inclu-
sion/exclusion criteria, ANS assessment techniques, and







Patient 13 3 1 30.8
Control 12 0 0 0.0(i.e., diabetes and CVD) and use of related medications
(i.e., various cardiac, antihypertensive and opioids).
Furthermore, in the absence of a pre-treatment base-
line evaluation and the inclusion of a wide age-range
of participants (19–79 years), it is difficult to assess
whether the reported ANS impairments have resulted
directly from the various cancers or anti-cancer ther-
apies. If, in fact, cancer(s) and anticancer therapies are
responsible for causing long term ANS impairment or
predisposing cancer survivors to related morbidity, the
development of protective therapies is imperative.
CV exercise training has been shown to preserve and
improve markers of ANS and CV health in other popu-
lations [49]. However, dysfunction of either the para-
sympathetic, sympathetic or sudomotor ANS branches
may independently compromise the ability of affected
cancer patients to exercise. More specifically, the shift
toward a “sympathetic dominant ANS balance”, caused
by either vagal withdrawal or sympathetic hyperactivity,
predisposes individuals to chronically higher resting
metabolic rates [3, 49], and therein an energetically un-
favorable state. Furthermore, parasympathetic damage
may hinder early exercise adaptations to [59, 60] and re-
covery rates from [61, 62], exercise. Inadequate sympathetic
adjustments are known to cause maladaptive blood pres-
sure responses [21] and may limit the attainment of max-
imal exercise performance [60, 63, 64]. Finally, aberrant
sweat responses, resulting from sudomotor dysfunction,
may compromise thermoregulation and place exercisingT2





12 2 0 18.2
11 0 0 0.0
Table 8 Good laboratory practice recommendations and considerations for ANS and CV testing in cancer
Patient recruitment, access and
retention
1. Recruit young adults from expanded age range (18–45 vs. 18–39).
• Boosts recruitment opportunity without exposing sample to preexisting ANS/CV morbidity and use of related
medications.
2. Prescreen for age and diagnosis (given the absence of underlying confounding morbidity).
3. YA cancer patients appear highly motivated and capable of participating in studies of this nature.
• Observational results - therefore, cannot generalize findings to intervention trials.
Pre-Chemotherapy baseline 4. Ensure unrestricted testing facility access.
• YAs are at a higher risk of late- and misdiagnosis [68, 69], which may increase the likelihood of advanced
staging at diagnosis and shorten the available pre-treatment testing window.
• Investigators should make every attempt to anticipate, screen for and test patients prior to their beginning
pre-treatment symptom management medication.
Test rerformance and tolerability 5. Proceed with CASS test battery as described.
• No differences in test tolerability or performance between patients and controls.
Use of potentially confounding
medication
6. Identify an assessment window which minimizes the influence of PCM.
• For 2–4 weeks/cycle treatment protocols, assessments should be made between 3 and 6 days prior to
subsequent treatment cycle.
• For 1 week/cycle treatment protocols, coordinating with the treating oncologist may be required to establish
the requisite assessment opportunity.
7. Record and report PCM use in all observation and intervention trials.• In addition to primary anti-cancer
treatments and commonly prescribed symptom-management medications (i.e. anti-emetic and pain-management),
we identified the occasional use of additional medications (i.e. antidepressant and sleep-aids) which may influence
ANS and CV testing.
Additional considerations 8. Systemic anticancer therapies are known to injure/perturb multiple CV system components.
∴Aberrant ANS test results may reflect end-organ dysfunction and not ANS dysfunction.
∴Include complementary CV and end-organ function tests in ANS-oncology research.
9. The single stage Astrand-Ryhming may lack sensitivity.
∴ Consider a submaximal or maximal incremental ramp exercise protocol instead.
10. Investigators should assess and account for differences in aerobic fitness, physical activity and fatigue levels,
given their relationships with measures of ANS function [3, 47, 51, 53].
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cise intolerance. Together, this evidence suggests that ANS
dysfunction may variably affect the exercise capacity of pa-
tients attempting to engage in it. It is also important to
consider that, even if exercise capacity is unaffected, ANS
dysfunction could potentially be an effect modifier for exer-
cise and multiple health outcomes. Drawing from this dis-
cussion, future research should explore and account for
both the direct- and moderator-effects of cancer-related
ANS dysfunction on established exercise-health outcome
relationships. Unfortunately, due to limitations in our study
design, we were unable to provide evidence of any relation-
ship between CV performance changes and the observed
ANS dysfunction. Possible reasons for this include: i) in-
sensitivity of the modified, single stage Astrand-Ryhming
protocol, ii) small sample size, and iii) wide range of normal
biologic variability within our control group.
Given the potential confounders of ANS testing in
cancer, and in an attempt to help localize cancer- and
treatment-related damage, it is likely necessary to con-
duct complementary assessments effector organ func-
tion (i.e. pulmonary, cardiac and vascular functiontests). Importantly, future investigations of autonomic
and CV function should make every effort to minimize
the influence of/report PCM use. Furthermore, to
standardize the evaluation of ANS function in cancer,
we strongly recommend the use of the CASS and com-
ponents therein. Finally, contrary to our hypotheses,
exposure to chemotherapy did not appear to cause signifi-
cant, additional impairment of the ANS and CV responses
to the CASS and exercise challenges. Although not statis-
tically supported, our main findings (diminished RSA and
QSART) may suggest a common cholinergic mechanism
of dysfunction. When considering the proposed mechan-
ism of acetylcholine and vagal function inhibition of pro-
inflammatory cytokine release [3], it is interesting to
speculate that if cancer-related parasympathetic dysfunc-
tion does exist, it may provide a pathway for CVD devel-
opment in cancer patients.
Limitations
As stated in the introduction and methods, the primary
purpose of this study was to assess the feasibility of
conducting concurrent ANS and CV assessments in
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cers. In keeping with pilot study recommendations [24],
we did not attempt to control for numerous con-
founders and covariates of ANS function when present-
ing our hypothesis-generating, physiology findings.
Additional study limitations include: i) heterogeneity of
diseases and related-treatments, ii) reliance on pre-
dicted, and not measured, VO2max scores as indicators
of aerobic fitness, iii) inaccurate patient reported out-
comes, iv) the use of the Brief Fatigue Inventory to
compare across cancer and non-cancer populations,
and v) unreported pre-test protocol violations and use
of PCMs. Therefore, we encourage readers to interpret
all of the reported physiology findings with extreme
caution.
Conclusions
The general aim of this study was to establish the feasi-
bility of testing autonomic and CV function in young
adult cancer patients undergoing treatment for cancer
by: i) identifying the methodological pitfalls and propos-
ing good laboratory practice criteria for ANS testing in
cancer, and ii) providing exploratory evidence of auto-
nomic perturbations in cancer patients using the CASS.
From a logistical standpoint, with a 98.4 % average suc-
cess rate in achieving the targeted FC, we are confident
that future investigations of autonomic function in can-
cer are possible. Cancer and chemotherapy are known to
impact effector organ and nervous system function.
However, due to the multiplicity of confounders on ANS
testing (i.e., lifestyle, age, comorbidity, cancer type, and
use of various anticancer therapies/supportive medica-
tions), the study of ANS function in cancer remains
challenging. As such, rigorous research, involving the
simultaneous evaluation of multiple CV system compo-
nents (i.e., effector organs, vasculature and nervous sys-
tem), is required to identify the mechanisms underlying
the observed acute and long-term CVD morbidity and
mortality risks in cancer survivors.
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